Currently Viewing:
Currently Reading
Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment
February 25, 2018 – Kaitlynn Ely
Study Finds Written Standardized Protocol Leads to Better Surgical Outcomes
February 24, 2018 – Samantha DiGrande
Current Risk-Adjustment Approach Underpaid Insurance Carriers for Part-Year Members
February 24, 2018 – Kaitlynn Ely
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 23, 2018 – Jaime Rosenberg
Survey Examines Whether Primary Care Doctors Gave Correct ADHD Diagnosis
February 23, 2018 – Allison Inserro
This Week in Managed Care: February 23, 2018
February 23, 2018
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
February 23, 2018 – Kelly Davio
Hydroxychloroquine Ineffective in Treating Hand Osteoarthritis Compared With Placebo
February 23, 2018 – Kaitlyn Ely
AJMC® in the Press, February 23, 2018
February 23, 2018 – AJMC Staff

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

AJMC Staff
Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.
Inhibition of cyclin-dependent kinase (CDK) 4/6 signaling has proven benefits for the majority of breast cancers that express the estrogen receptor or progesterone receptor. However, CDK 4/6 inhibitors are associated with hematological toxicities and febrile neutropenia (FN).

An abstract presented at the American Society of Clinical Oncology’s 2017 Palliative and Supportive Care in Oncology Symposium analyzed the risk of hematological toxicities and FN in patients with breast cancer using a literature search of MEDLINE and EMBASE databases and meeting abstracts.

Studies included were randomized controlled trials that mentioned anemia, thrombocytopenia, leukopenia, neutropenia, and neutropenic fever as adverse effects. In addition, studies had to compare CDK 4/6 inhibitors based on regimen and a control group with patients with hormone receptor–positive human epidermal growth factor receptor 2 (HER-2)–negative metastatic breast cancer.

The meta-analysis included 5 trials with 2671 patients total, with 4 of the studies in phase 3 and the other in phase 2.

The study arms used palbociclib-letrozole, palbociclib-fulvestrant, ribociclib-letrozole, and abemaciclib-fulvestrant, and the control arms used placebo with either letrozole or fulvestrant. The analysis found that the pooled risk of neutropenic fever was statistically significant at 4.26.

The relative risks of all-grade side effects were:
  • Anemia, 3.77
  • Thrombocytopenia, 9.69
  • Leukopenia, 11.68
  • Neutropenia, 14.09
The relative risks of high-grade adverse effects were:
  • Anemia, 2.55
  • Thrombocytopenia, 7.08
  • Leukopenia, 33.58
  • Neutropenia, 40.33
“CDK 4/6 inhibitors based regimen significantly contributed to all hematological toxicities as well as febrile neutropenia,” the authors concluded. “These toxicities affect patients’ quality of life, add financial burden and may lead to drug dosing inconsistencies.”

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!